After FDA warning: The dangers you must know about weight loss injections

The FDA has ordered a warning to be added to GLP-1 drugs (Ozempic, Wegovy) due to a suspected rare optic nerve injury. The AMLI association reassures that this is an extremely rare phenomenon and warns against stopping treatment without medical supervision.

The U.S. Food and Drug Administration (FDA) has ordered a warning to be added to the popular GLP-1 drugs, including Ozempic and Wegovy, following concerns about a rare optic nerve injury that could lead to permanent vision loss. An analysis of 126 clinical trials found 6.4 cases of optic nerve injury per 100,000 patient-years among users, compared to 3.8 in control groups. The AMLI association, representing diabetes specialist nurses in Israel, reassures that this is an extremely rare phenomenon and warns that stopping treatment without medical supervision could endanger patients. Symptoms include sudden blurred vision, dark spots in the visual field, and partial or complete vision loss, usually in one eye and without pain. The key message is not to stop treatment independently and to consult an ophthalmologist if symptoms occur.